The Pharma Letter Podcast — Episode 20 — Galapagos update—with CEO Paul Stoffels

Simon Wentworth

2 February 2023

2-2

More on this story...

R&D U-turn sees Galapagos ditching liver and kidney programs

4 November 2022

Belgian biotech Galapagos goes on a spending spree

22 June 2022

NICE recommends Galapagos' Jyseleca in UC

1 June 2022

Strategic overhaul continues apace at Galapagos, with new R&D deal

31 March 2023

Companies featured in this story

More ones to watch >

Today's issue

Alloy and Takeda team up on CAR-T cell platform

Alloy and Takeda team up on CAR-T cell platform

21 November 2024

Eisai announces launch of Rozebalamin and Tasfygo

21 November 2024

Merck: a relentless pursuit of the best outcomes for the entire MS community

21 November 2024

Cidara to raise up to $105 million in private placement

21 November 2024

Novartis upgrades mid-term guidance; buys Kate Thera

21 November 2024

FDA approves Jazz’s Ziihera for HER2+ biliary tract cancer

21 November 2024

Lilly and Laekna team up on novel obesity drugs

21 November 2024

Company Spotlight

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

More Features in Biotechnology

Alloy and Takeda team up on CAR-T cell platform

21 November 2024

Cidara to raise up to $105 million in private placement

21 November 2024

FDA approves Jazz’s Ziihera for HER2+ biliary tract cancer

21 November 2024

Lilly and Laekna team up on novel obesity drugs

21 November 2024

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze